PICKERING, ON, Nov. 9, 2021 /CNW/ – Ayurcann Holdings Corp. (CSE: AYUR) (FSE: 3ZQ0) (the “Company” or “Ayurcann“) a Canadian extraction company specializing in the processing of cannabis and hemp to produce oils and various derivative products, is pleased to announce the launch of their high potency THC and CBD-infused topical skincare line; GLOW. Ayurcann will launch their line of GLOW products through the Ontario Cannabis Store (the “OCS“). Products will be made available through additional adult-use channels including the provincial retailers and storefronts across Ontario.
To start, Ayurcann will be launching GLOW’s Day cream and Night cream combo pack. The product’s quick absorbing formula works fast to enhance applied to areas. Harnessing the power of the cannabis plant, GLOW’s non-psychoactive formula uses both THC and CBD blended with high-quality natural botanicals and essential oils.
The initial product launch includes two SKUs: GLOW Day Cream and GLOW Night Cream. GLOW Day Cream contains a total of 1000mg of CBD, while the Night Cream contains a mix of 500mg THC and 500mg of CBD. With the introduction of one of the highest concentrations of active cannabinoids on the market in a topical format, Ayurcann’s strategy is to expand market share in extract and extract derivatives while providing exceptional products to consumers. GLOW is poised to be a top choice among consumers entering the cannabis space in search of topical products due to its premium quality and value-based price points. In a 2021 report on Canadian cannabis consumers, Deloitte noted that nearly half of new users are more likely to prefer CBD-only products with 34% of existing consumers citing general health & wellness as drivers of CBD consumption.
“We are thrilled to announce GLOW’s initial entrance into the Canadian market through the OCS, where we are optimistic about its market potential as an industry leading cannabinoid-based topical line. We have been pleasantly surprised by the initial interest from consumers and retailers for these products and believe they will help set the standard for cannabinoid-based topicals,” states Igal Sudman, CEO of Ayurcann.
About Ayurcann Holdings Corp.
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward- looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including but not limited to statements relating to the Company’s expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, but are not limited to, failure to obtain regulatory approval, ability to increase production at the Company’s facilities, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, Further, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have significant economic and geopolitical impacts that may adversely affect the Company’s business, financial condition and/or results of operations. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
SOURCE Ayurcann Holdings Corp.
For further information: Igal Sudman, Chairman and Chief Executive Officer, Ayurcann Holdings Corp., Tel: 905-492-3322 , Email: email@example.com; Investor Relations: Ryan Bilodeau, Tel: 416-910-1440, Email: firstname.lastname@example.org